Skip to main content

Table 4 Incidence of adverse outcomes in new-onset NSTEMI patients according to the TBIL tertiles

From: Serum total bilirubin and long-term prognosis of patients with new-onset non-ST elevation myocardial infarction: a cohort study

Variables 1st tertile
< 10.23 umol/L
(n = 109)
2nd tertile
10.23–14.30 μmol/L
(n = 109)
3rd tertile
≥ 14.30 μmol/L
(n = 109)
χ2 p value
MACCEs, n (%) 7 (6.4) 23 (21.1) 27 (24.8) 14.278 0.001
 Sudden cardiac death, n (%) 7 (6.4) 5 (4.6) 8 (7.3) 0.746 0.689
 Recurrent MI, n (%) 3 (2.8) 6 (5.5) 7 (6.4) 1.709 0.426
 Revascularization, n (%) 5 (4.6) 14 (12.8) 18 (16.5) 9.041 0.011
 Stroke, n (%) 0 (0.0) 4 (3.7) 4 (3.7) 6.587 0.037
 Stent thrombosis, n (%) 4 (3.7) 5 (4.6) 4 (3.7) 0.157 0.925
All-cause mortality, n (%) 4 (3.7) 8 (7.3) 11 (10.1) 3.461 0.177
  1. Values of p < 0.05 are indicated in bold
  2. MI, myocardial infarction; MACCEs, major adverse cardiac and cerebrovascular events